Yarkoni E, Rapp H J
Infect Immun. 1978 Sep;21(3):1029-32. doi: 10.1128/iai.21.3.1029-1032.1978.
BCG cell wall skeletons (SK) derived from BCG cell walls (CW) by treatment with proteolytic enzymes and organic solvents were tested for their potency to cause regression of a transplanted guinea pig hepatoma. On a weight basic, SK were as effective as CW in causing tumor regression, and they, as well as purified protein derivative of mycobacteria, provoked delayed cutaneous hypersensitivity reactions in animals immunized with CW or with SK. On a weight basis, CW were more active than SK in eliciting delayed cutaneous hypersensitivity in sensitized guinea pigs whether the animals were immunized with CW or with SK. In unimmunized animals the inflammatory response to intradermally administered CW was greater than that evoked by SK. CW and SK provoked delayed cutaneous hypersensitivity reactions of similar strength in animals immunized with living BCG. This study provided no compelling reasons for using SK instead of CW in clinical trials of cancer treatment by mycobacterial vaccines.
通过用蛋白水解酶和有机溶剂处理卡介苗细胞壁(CW)而获得的卡介苗细胞壁骨架(SK),对其使移植的豚鼠肝癌消退的效力进行了测试。以重量为基础,SK在引起肿瘤消退方面与CW一样有效,并且它们以及分枝杆菌的纯化蛋白衍生物,在经CW或SK免疫的动物中引发了迟发型皮肤超敏反应。以重量为基础,无论是用CW还是SK免疫动物,在致敏豚鼠中,CW在引发迟发型皮肤超敏反应方面比SK更活跃。在未免疫的动物中,对皮内注射CW的炎症反应大于SK所引发的炎症反应。CW和SK在经活卡介苗免疫的动物中引发了强度相似的迟发型皮肤超敏反应。这项研究没有提供令人信服的理由在分枝杆菌疫苗癌症治疗的临床试验中使用SK而非CW。